Potency Meets Precision in Nano-optimized Chemotherapeutics

Artavazd Arumov; Asaad Trabolsi; Jonathan H Schatz

doi:10.1016/j.tibtech.2021.03.004

Potency Meets Precision in Nano-optimized Chemotherapeutics

Trends Biotechnol. 2021 Oct;39(10):974-977. doi: 10.1016/j.tibtech.2021.03.004. Epub 2021 Apr 5.

Authors

Artavazd Arumov¹, Asaad Trabolsi², Jonathan H Schatz³

Affiliations

¹ Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, FL, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: aarumov@miami.edu.
² Division of Hospital Medicine, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
³ Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA; Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: jschatz@med.maimi.edu.

Abstract

Chemotherapy remains the most widely used cancer treatment modality. Nanotechnology provides exciting opportunities to improve these drugs, transforming decades-old generic treatments into precise new medicines. We illustrate the potential of recent advances in nanotechnology-enhanced therapy focusing on diffuse large B-cell lymphoma (DLBCL); the most common hematologic malignancy.

Keywords: cancer; drug delivery; lymphoma; nanotechnology; precision medicine; therapeutics.

MeSH terms

Humans
Lymphoma, Large B-Cell, Diffuse*
Nanotechnology
Precision Medicine

Grants and funding

P30 CA240139/CA/NCI NIH HHS/United States